¶ Inclusion Body Myositis (IBM)
Inclusion Body Myositis (Ibm) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Inclusion body myositis (IBM), also known as sporadic inclusion body myositis (sIBM), is the most common acquired inflammatory myopathy in adults over the age of 50. [It is a chronic, progressive muscle disease characterized by a distinctive dual-mechanism pathogenesis involving both an inflammatory/autoimmune component and a degenerative component with protein aggregation closely paralleling that seen in neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis.[1]
Unlike other inflammatory myopathies such as polymyositis and dermatomyositis, IBM is refractory to immunosuppressive therapy — a clinical hallmark that underscores the importance of its degenerative pathology. The disease causes slowly progressive, asymmetric weakness preferentially affecting the quadriceps femoris and deep finger flexors, with dysphagia occurring in 30-80% of patients.[2] IBM shares key pathological features with major neurodegenerative diseases, including TDP-43 cytoplasmic aggregation, Amyloid-Beta accumulation, tau](/proteins/tau-protein) hyperphosphorylation, and p62/ubiquitin-positive inclusions.[3]
Diagnostic delay averages 5-8 years from symptom onset, and no disease-modifying treatment currently exists. The 2024 European Neuromuscular Centre (ENMC) criteria provide the current diagnostic standard.[4]
- Prevalence: 5-50 per million adults overall; up to 51 per million in adults over 50 years (Australia, highest reported)
- Incidence: Approximately 2.5 per million per year (Sweden)[5]
- Age at onset: Mean approximately 64 years (range 45-80); extremely rare before age 45
- Sex: Male predominance with a male-to-female ratio of 2:1 to 3:1
- Ethnicity: More prevalent in Caucasian populations; lower reported rates in Asian and African populations
- Mortality: 10-year survival 36-42% vs 59% in age-matched controls; mean age at death 79.3 years vs 83.6 years in controls[6]
- Disability: Progressive weakness leading to wheelchair dependence at a mean of approximately 10.5 years from onset
IBM pathogenesis involves two intertwined processes: an inflammatory/autoimmune arm and a degenerative/protein aggregation arm. The relative contribution of each remains actively debated.[7]
The inflammatory arm of IBM is characterized by:
- CD8+ cytotoxic T cell invasion: Endomysial CD8+ T cells surround and invade non-necrotic muscle fibers, suggesting an antigen-directed immune response. These T cells are highly differentiated, clonally restricted, and express markers of cytotoxicity including perforin and granzyme B
- MHC class I upregulation: Sarcolemmal MHC-I expression is universally upregulated in IBM muscle fibers, even those without visible inflammatory infiltrates
- NF-κB activation: The NF-κB signaling pathway is activated in IBM muscle fibers, driving both inflammatory gene expression and protein aggregation cascades
- Anti-cN1A autoantibodies: Antibodies against cytosolic 5'-nucleotidase 1A are found in 33-76% of IBM patients with 87-100% specificity, supporting an autoimmune component[8]
- Immunosenescence: Highly differentiated T cells with features of immunosenescence (KLRG1+, CD57+, CD28-) dominate the IBM muscle infiltrate
The degenerative arm features protein aggregation strikingly similar to that seen in neurodegenerative brain diseases:
- TDP-43 mislocalization and aggregation: TDP-43 is mislocalized from the nucleus to the cytoplasm and forms phosphorylated, ubiquitinated aggregates in approximately 78% of IBM biopsies, mirroring the TDP-43 Proteinopathy seen in ALS and frontotemporal dementia[9]
- Amyloid-Beta accumulation: Congophilic amyloid deposits containing amyloid-beta peptides are found in IBM vacuolated fibers
- Tau(/proteins/tau-protein) hyperphosphorylation: Paired helical filament-associated phospho-tau] accumulates in IBM muscle, resembling the tau pathology] of Alzheimer's disease
- p62/SQSTM1 and ubiquitin inclusions: p62 and ubiquitin-positive aggregates are a hallmark pathological finding
- Rimmed vacuoles: Autophagic vacuoles lined with basophilic granular material, representing failed autophagic clearance
- Mitochondrial dysfunction: Cytochrome c oxidase-negative fibers and mitochondrial DNA deletions are prominent[10]
- Impaired autophagy and proteasome function: Both the ubiquitin-proteasome system and autophagy-lysosomal pathway are impaired, leading to protein accumulation
Whether inflammation triggers degeneration or protein aggregation provokes an immune response remains unresolved. Greenberg (2019) argued that degeneration is the primary event, with inflammation as a secondary response. However, Britson et al. (2022) demonstrated in a human muscle xenograft model that CD8+ T cells can drive many degenerative features including TDP-43 mislocalization, providing evidence that inflammation may initiate the degenerative cascade.[11]
IBM has a strong genetic association with the major histocompatibility complex:
- HLA-DRB1*03:01:01 is the primary risk allele (odds ratio approximately 9.2), with the amino acid arginine at position 74 in the DRB1 peptide-binding groove identified as the key risk residue[12]
- Protective alleles: DRB401:01:01, DQA101:02:01, and DRB1*15:01 are associated with reduced IBM risk
- Individuals carrying risk alleles without protective alleles have approximately 14-fold increased risk compared to the general population
Sporadic IBM must be distinguished from hereditary inclusion body myopathy (hIBM/GNE myopathy), which is caused by recessive mutations in the GNE gene and typically presents in younger patients without inflammatory infiltrates. VCP-associated [multisystem proteinopathy] is another hereditary condition with IBM-like features caused by mutations in the VCP gene.
- Quadriceps femoris: Early and severe weakness leading to difficulty climbing stairs, rising from chairs, and falls
- Deep finger flexors: Weakness of flexor digitorum profundus causes difficulty gripping objects, turning keys, and buttoning
- Asymmetry: Weakness is characteristically asymmetric, particularly early in the disease course
- Other affected muscles: Wrist flexors, ankle dorsiflexors, and hip flexors become involved as the disease progresses
- Relative sparing: Deltoid, biceps, and triceps muscles are typically spared until late stages
Dysphagia occurs in 30-80% of IBM patients and is a significant cause of morbidity and mortality. Aspiration pneumonia is the leading cause of death in IBM.[6]
The revised 2024 ENMC criteria use a two-step approach:[4]
Step 1 - Clinical suspicion: Age over 45, progressive proximal and/or distal weakness, finger flexor or quadriceps weakness
Step 2 - Confirmatory investigations:
- Muscle biopsy: Endomysial CD8+ T cell inflammation invading non-necrotic fibers, rimmed vacuoles, protein aggregates
- Electromyography: Mixed myopathic and neuropathic pattern
- Anti-cN1A antibodies: Present in 33-76% of cases with high specificity
- MRI: Fatty infiltration of quadriceps and forearm flexors with relative sparing of posterior thigh
¶ Current Landscape
No disease-modifying treatment exists for IBM.[1]
- Arimoclomol: Phase II/III RCT (n=152) showed no significant benefit[13]
- Bimagrumab: Increased muscle mass but failed to improve function
- Alemtuzumab: Reduced T cell counts but did not slow progression
- IVIg: Modest, transient improvement only
- Sirolimus: Phase III OPTIMISM trial targeting autophagy enhancement, results expected H1 2026[14]
- Anti-KLRG1 approaches: Targeting senescent CD8+ T cells
- autophagy enhancers: Enhancing clearance of protein aggregates
The TDP-43 pathology in IBM closely mirrors that in ALS and FTD. Lynch et al. (2024) demonstrated that IBM muscle TDP-43 aggregates have prion-like seeding capacity.[15]
¶ Amyloid and Tau Pathology
The accumulation of Amyloid-Beta and hyperphosphorylated tau](/proteins/tau-protein) in IBM muscle mirrors Alzheimer's disease pathology.
¶ Autophagy and Proteasome Dysfunction
Impaired autophagy and [ubiquitin-proteasome] function parallels the proteostasis failure seen across all major neurodegenerative diseases.
The study of Inclusion Body Myositis (Ibm) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Anderson KR, Lloyd TE. Inclusion body myositis: an update. Curr Opin Rheumatol. 2025;37:41-48]https://pubmed.ncbi.nlm.nih.gov/39469805/)
- [Shelly S et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021;96:e2653-e2661]https://pubmed.ncbi.nlm.nih.gov/33879596/)
- [Askanas V, Engel WK, Nogalska A. Sporadic inclusion-body myositis: a degenerative muscle disease. Biochim Biophys Acta. 2015;1852:633-643]https://pubmed.ncbi.nlm.nih.gov/25149038/)
- [Lilleker JB et al. ENMC 2024 diagnostic criteria for inclusion body myositis. Neuromuscul Disord. 2024;38:16-25]https://pubmed.ncbi.nlm.nih.gov/38522330/)
- [Lindgren U et al. Epidemiology of inclusion body myositis in Sweden. Rheumatology. 2023;62:847-854]https://pubmed.ncbi.nlm.nih.gov/35596584/)
- [Price MA et al. Mortality and causes of death in patients with sporadic inclusion body myositis. J Rheumatol. 2018;45:1471-1476]https://pubmed.ncbi.nlm.nih.gov/30008457/)
- [Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15:257-272]https://pubmed.ncbi.nlm.nih.gov/30837708/)
- [Herbert MK et al. Disease specificity of autoantibodies to cytosolic 5-nucleotidase 1A. Ann Rheum Dis. 2016;75:696-701]https://pubmed.ncbi.nlm.nih.gov/25714931/)
- [Weihl CC et al. TDP-43 accumulation in inclusion body myopathy muscle. J Neurol Neurosurg Psychiatry. 2008;79:1186-1189]https://pubmed.ncbi.nlm.nih.gov/18796596/)
- [Brady S, Poulton J, Muller S. Inclusion body myositis: correcting impaired mitochondrial and lysosomal autophagy. Autoimmun Rev. 2024;23:103644]https://pubmed.ncbi.nlm.nih.gov/39306221/)
- [Britson KA et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model. Sci Transl Med. 2022;14:eabi9196]https://pubmed.ncbi.nlm.nih.gov/35044790/)
- [Slater N et al. HLA genotyping reveals shared and distinct risk alleles for sporadic IBM. Ann Rheum Dis. 2024;83:520-529]https://pubmed.ncbi.nlm.nih.gov/38043487/)
- [Machado PM et al. Safety and efficacy of arimoclomol for IBM: a multicentre RCT. Lancet Neurol. 2023;22:900-911]https://pubmed.ncbi.nlm.nih.gov/37739573/)
- [Badrising UA et al. OPTIMISM: a phase 3 trial of sirolimus for IBM. Neuromuscul Disord. 2025;47:104471]https://pubmed.ncbi.nlm.nih.gov/40018746/)
- [Lynch EM et al. Seeding-competent TDP-43 persists in human patient and mouse muscle. Sci Transl Med. 2024;16:eadp5730]https://pubmed.ncbi.nlm.nih.gov/39602508/)